Shantha Biologics Announces Cartridge Fill-Finish Collaboration
The agreement with Novo Nordisk reflects Shantha Biologics' continued focus on high-quality manufacturing execution and its role as a trusted partner to global healthcare companies. The collaboration will be governed by the parties' agreed contractual framework and carried out in accordance with applicable quality, compliance, and regulatory requirements.
"We are pleased to enter into this collaboration, which reflects the confidence placed in Shantha Biologics' capabilities and our commitment to reliable, high-quality cartridge fill-finish services," said Dr. Vishy Chebrol, Director,
No financial terms or further details of the agreement are being disclosed.
About Shantha Biologics
Shantha Biologics is a pharmaceutical manufacturing company based in Hyderabad, India, with capabilities spanning vaccines, biologics, and specialized sterile manufacturing. The company operates purpose-built sterile fill-finish capacity, including cartridge filling, and partners with global pharmaceutical and biotechnology companies to deliver high-quality development and aseptic manufacturing that meets international quality and compliance standards.
Media Contact:
Dr MRK Raju +91 996 358 1033 | Sashi Pochimcharla +91 994 905 4060 |
Logo: https://mma.prnewswire.com/media/3002474/Shantha_Biologics_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/shantha-biologics-announces-cartridge-fill-finish-collaboration-302814558.html
SOURCE Shantha Biologics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ProCapture System is Now a Full-Store Solution for Lint Collection
- Lovehoney Reveals the Sexiest Cities in the U.S. With New Sex Map
- WEC Energy Group's 2025 Corporate Responsibility Report highlights reliability, sustainability and long-term value
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share